Display options
Cite
Jilek JL, Frost KL, Jacobus KA, et al. Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity. Acta Pharm Sin B. 2021;11(12):3869-3878doi: 10.1016/j.apsb.2021.05.030.
Jilek, J. L., Frost, K. L., Jacobus, K. A., He, W., Toth, E. L., Goedken, M., & Cherrington, N. J. (2021). Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity. Acta pharmaceutica Sinica. B, 11(12), 3869-3878. https://doi.org/10.1016/j.apsb.2021.05.030
Jilek, Joseph L, et al. "Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity." Acta pharmaceutica Sinica. B vol. 11,12 (2021): 3869-3878. doi: https://doi.org/10.1016/j.apsb.2021.05.030
Jilek JL, Frost KL, Jacobus KA, He W, Toth EL, Goedken M, Cherrington NJ. Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity. Acta Pharm Sin B. 2021 Dec;11(12):3869-3878. doi: 10.1016/j.apsb.2021.05.030. Epub 2021 Jun 02. PMID: 35024313; PMCID: PMC8727892.
Copy Download .nbib Format: NLM
Share it on

Acta Pharm Sin B. 2021 Dec;11(12):3869-3878. doi: 10.1016/j.apsb.2021.05.030. Epub 2021 Jun 02.

Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity.

Acta pharmaceutica Sinica. B

Joseph L Jilek, Kayla L Frost, Kevyn A Jacobus, Wenxi He, Erica L Toth, Michael Goedken, Nathan J Cherrington

Affiliations

  1. Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85724, USA.
  2. Rutgers Translational Sciences, Rutgers University, Piscataway, NJ 08901, USA.

PMID: 35024313 PMCID: PMC8727892 DOI: 10.1016/j.apsb.2021.05.030

Abstract

Disease-mediated alterations to drug disposition constitute a significant source of adverse drug reactions. Cisplatin (CDDP) elicits nephrotoxicity due to exposure in proximal tubule cells during renal secretion. Alterations to renal drug transporter expression have been discovered during nonalcoholic steatohepatitis (NASH), however, associated changes to substrate toxicity is unknown. To test this, a methionine- and choline-deficient diet-induced rat model was used to evaluate NASH-associated changes to CDDP pharmacokinetics, transporter expression, and toxicity. NASH rats administered CDDP (6 mg/kg, i.p.) displayed 20% less nephrotoxicity than healthy rats. Likewise, CDDP renal clearance decreased in NASH rats from 7.39 to 3.83 mL/min, renal secretion decreased from 6.23 to 2.80 mL/min, and renal CDDP accumulation decreased by 15%, relative to healthy rats. Renal copper transporter-1 expression decreased, and organic cation transporter-2 and ATPase copper transporting protein-7b increased slightly, reducing CDDP secretion. Hepatic CDDP accumulation increased 250% in NASH rats relative to healthy rats. Hepatic organic cation transporter-1 induction and multidrug and toxin extrusion protein-1 and multidrug resistance-associated protein-4 reduction may contribute to hepatic CDDP sequestration in NASH rats, although no drug-related toxicity was observed. These data provide a link between NASH-induced hepatic and renal transporter expression changes and CDDP renal clearance, which may alter nephrotoxicity.

© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Keywords: ATP7, ATPase copper transporting protein; CDDP, cisplatin; CTR, copper transporter; Cisplatin; DDTC, diethyldithiocarbamate; DT, drug transporter; Drug transporter; GFR, glomerular filtration rate; LC–MS/MS, liquid chromatography–tandem mass spectrometry; MATE, multidrug and toxin extrusion protein; MCD, methionine- and choline-deficient diet; NAFLD, nonalcoholic fatty liver disease; NASH; NASH, nonalcoholic steatohepatitis; Nephrotoxicity; Nonalcoholic steatohepatitis; OCT, organic cation transporter; P-gp, p-glycoprotein; PK, pharmacokinetics

References

  1. Drug Metab Dispos. 2014 Apr;42(4):586-95 - PubMed
  2. Br J Pharmacol. 2011 Dec;164(7):1817-25 - PubMed
  3. Mol Pharmacol. 2009 Oct;76(4):843-53 - PubMed
  4. Physiol Rep. 2017 May;5(9): - PubMed
  5. Biochem Pharmacol. 1994 Aug 3;48(3):453-9 - PubMed
  6. Mol Pharmacol. 2014 May;85(5):715-22 - PubMed
  7. Cancer Treat Rep. 1983 Feb;67(2):169-72 - PubMed
  8. Biochem Pharmacol. 1987 Jun 15;36(12):1925-32 - PubMed
  9. J Pharm Sci. 2017 Sep;106(9):2282-2294 - PubMed
  10. Mol Pharmacol. 2008 Feb;73(2):461-8 - PubMed
  11. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14298-302 - PubMed
  12. Cancer Chemother Pharmacol. 1982 Dec;10(1):51-4 - PubMed
  13. Mol Pharmacol. 2003 Aug;64(2):466-73 - PubMed
  14. Drug Metab Dispos. 2015 Feb;43(2):266-72 - PubMed
  15. Biomed Pharmacother. 2009 Feb;63(2):79-85 - PubMed
  16. Vet Comp Oncol. 2008 Mar;6(1):1-18 - PubMed
  17. Biochem Pharmacol. 2011 Mar 1;81(5):563-8 - PubMed
  18. Mol Pharmacol. 2002 Nov;62(5):1154-9 - PubMed
  19. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11199-204 - PubMed
  20. Clin Pharmacol Ther. 2009 Oct;86(4):396-402 - PubMed
  21. Biochem Pharmacol. 2016 Sep 1;115:144-51 - PubMed
  22. Cancer Treat Rep. 1978 Dec;62(12):2125-6 - PubMed
  23. Clin J Am Soc Nephrol. 2010 Dec;5(12):2166-71 - PubMed
  24. J Pharm Pharmacol. 2000 Nov;52(11):1345-53 - PubMed
  25. Scientifica (Cairo). 2012;2012:473829 - PubMed
  26. J Pharmacol Exp Ther. 1980 Jun;213(3):551-6 - PubMed
  27. Br J Clin Pharmacol. 2015 Feb;79(2):222-40 - PubMed
  28. J Am Soc Nephrol. 2003 Jan;14(1):1-10 - PubMed
  29. Biomed Res Int. 2018 Sep 12;2018:1462802 - PubMed
  30. Cancer Res. 1993 Nov 1;53(21):5225-32 - PubMed
  31. Clin Cancer Res. 2008 Jun 15;14(12):3875-80 - PubMed
  32. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 1;1046:243-249 - PubMed
  33. Diabetes. 2015 Sep;64(9):3305-13 - PubMed
  34. Cancer Res. 2000 Mar 1;60(5):1312-6 - PubMed
  35. Biochem J. 1997 Jul 1;325 ( Pt 1):207-16 - PubMed

Publication Types